Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)

Clinical Epigenetics

Review

Suwen Lin¹  Shikai Jin²  Liwen Zhang²  Jingwen Yang²  Jun Du³  Yuping Gong⁴  Guang Lu⁵  Weiwei Mou⁶ 

[1] Clinical Research Institute, Shenzhen Peking University – The Hong Kong University of Science and Technology Medical Center, 518036, Shenzhen, Guangdong, People’s Republic of China;Department of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, People’s Republic of China;Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 200127, Shanghai, People’s Republic of China;Department of Hematology, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, People’s Republic of China;Department of Hematology, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, People’s Republic of China;Department of Hematology, Shengli Oilfield Central Hospital, 257034, Dongying, Shandong, People’s Republic of China;Department of Pediatrics, Shengli Oilfield Central Hospital, 257034, Dongying, Shandong, People’s Republic of China;

关键词: Histone deacetylase;    HDACi;    PTCL;    Romidepsin;    Belinostat;    Chidamide;   

DOI  :  10.1186/s13148-023-01531-8

 received in 2023-02-28, accepted in 2023-07-05,  发布年份 2023

来源: Springer

【 摘 要 】

Peripheral T-cell lymphomas (PTCLs) are a group of highly aggressive malignancies with generally poor prognoses, and the first-line chemotherapy of PTCL has limited efficacy. Currently, several novel targeted agents, including histone deacetylase inhibitors (HDACis), have been investigated to improve the therapeutic outcome of PTCLs. Several HDACis, such as romidepsin, belinostat, and chidamide, have demonstrated favorable clinical efficacy and safety in PTCLs. More novel HDACis and new combination therapies are undergoing preclinical or clinical trials. Mutation analysis based on next-generation sequencing may advance our understanding of the correlation between epigenetic mutation profiles and relevant targeted therapies. Multitargeted HDACis and HDACi-based prodrugs hold promising futures and offer further directions for drug design.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

12888_2023_5012_Article_IEq4.gif

12888_2023_5012_Article_IEq2.gif

40517_2023_261_Article_IEq36.gif